NCT00492544View on ClinicalTrials.gov

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 2, 2007

Primary Completion Date

March 28, 2008

Study Completion Date

March 28, 2008

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

Cervarix™ (HPV-16/18 L1 VLP AS04)

Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.

Trial Locations (5)

360-0812

GSK Investigational Site, Saitama

360-0846

GSK Investigational Site, Saitama

136-0073

GSK Investigational Site, Tokyo

154-0024

GSK Investigational Site, Tokyo

Unknown

GSK Investigational Site

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00492544 - Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age | Biotech Hunter | Biotech Hunter